N.R. MUKHAMADEEVA, O.V. KACHEMAEVA, R.M. GALIMOVA, I.V. BUZAEV, A.V. SAMORODOV, N.SH. ZAGIDULLIN

 Bashkir State Medical University, Ufa

Contact details:

Mukhamadeeva N.R. — postgraduate student of the Department of Internal Medicine

Address: 32 Zaki Validi St., 450076 Ufa, Russian Federation, tel.: +7-963-235-16-18, e-mail: ishtu2013@yandex.ru

Atherosclerosis and ischemic heart disease (IHD) are among the most common diseases and the leading causes of death in developed countries. Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder. Research show that approximately 80% of PD patients have cardiovascular diseases, while the need for their early diagnosis and treatment is often underestimated. Some manifestations of CVD may be regarded as non-motor manifestations of PD. However, the connection between PD and cardiocerebrovascular diseases remains controversial. The mechanisms linking atherosclerosis and IHD with PD may include chronic inflammation and oxidative stress. Inflammatory markers such as C-reactive protein and interleukins play a crucial role in the progression of these diseases. Oxidative stress is also considered an important factor in the pathogenesis of neurodegeneration in PD. Genetic studies reveal a relationship between genes associated with PD and cardiovascular diseases. Non-coding microRNAs (miRNAs) may also influence regulation of genes related to these conditions. Further research is necessary to better understand the mechanisms of interaction between CVD and Parkinson’s disease, which could lead to improved diagnostics and the development of personalized treatment methods.

Key words: cardiovascular diseases, risk factors, Parkinson’s disease, biomarkers.

REFERENCES

1. Krishnan S. et al. Do nonmotor symptoms in Parkinson’s disease differ from normal aging? Movement Dis, 2011, vol. 26 (11), pp. 2110–2113.
2. Yazdani A.N. et al. Biomarkers to monitor the prognosis, disease severity, and treatment efficacy in coronary artery disease. Expert Rev. Cardiovasc. Ther, 2023, vol. 21 (10), pp. 675–692.
3. Gonçalves V.C. et al. Heart matters: cardiac dysfunction and other autonomic changes in Parkinson’s disease. The Neuroscientist, 2022, vol. 28 (6), pp. 530–542.
4. Cuenca-Bermejo L. et al. Cardiac changes in Parkinson’s disease: lessons from clinical and experimental evidence. Int. J. Mol. Sci, 2021, vol. 22 (24), p. 13488.
5. Sheen S.H. et al. The relationship between Parkinson’s disease and acute myocardial infarction in Korea: a nationwide longitudinal cohort study. J. Korean Neurosurg. Soc, 2022, vol. 65 (4), pp. 507–513.
6. Chua S.K.K. et al. Association between Parkinson’s disease and coronary artery disease: A systematic review and meta-analysis. J. Parkinson’s Dis, 2022, vol. 12 (6), pp. 1737–1748.
7. Hu Y., Xu S. Association between Parkinson’s disease and the risk of adverse cardiovascular events: a systematic review and meta-analysis. Front. Cardiovasc. Med, 2023, vol. 10, pp. 1284826.
8. Zhou Z. et al. Relationship between Parkinson’s disease and cardio-cerebrovascular diseases: a Mendelian randomized study. Sci. Rep, 2023, vol. 13 (1), pp. 20428.
9. Oosterwegel M.J. et al. The effect of cardiovascular risk on disease progression in de novo Parkinson’s disease patients: An observational analysis. Front. Neurol, 2023, vol. 14, pp. 1138546.
10. Lohmann S. et al. Ischemic stroke causes Parkinson’s disease-like pathology and symptoms in transgenic mice overexpressing alpha-synuclein. Acta Neuropathol. Commun, 2022, vol. 10 (1), p. 26.
11. Sundbøll J. et al. Risk of Parkinson disease and secondary parkinsonism in myocardial infarction survivors. J. Am. Heart Assoc, 2022, vol. 11 (5), p. e022768.
12. Değirmenci H., Bakirci E.M., Hamur H. Cardiac effects of Parkinson’s disease. Open J. Parkinson’s Dis. Treat, 2020, vol. 3 (1), pp. 006–007.
13. Lee B. et al. Clinical and non-clinical cardiovascular disease associated pathologies in Parkinson’s disease. Int. J. Mol. Sci, 2023, vol. 24 (16), pp. 12601.
14. Cappannoli L. et al. Inflammation in ischemic heart disease: pathophysiology, biomarkers, and therapeutic implications. Front. Cardiovasc. Med, 2024, vol. 11, p. 1469413.
15. Liu T.W., Chen C.M., Chang K.H. Biomarker of neuroinflammation in Parkinson’s disease. Int. J. Mol. Sci, 2022, vol. 23 (8), p. 4148.
16. Trist B.G., Hare D.J., Double K.L. Oxidative stress in the aging substantia nigra and the etiology of Parkinson’s disease. Aging Cell, 2019, vol. 18 (6), p. e13031.
17. Generoso D. et al. Oxidative stress in the murine model of extraparenchymal neurocysticercosis. Microorganisms, 2024, vol. 12 (9), p. 1860.
18. Nandi A. et al. Role of catalase in oxidative stress‐and age‐associated degenerative diseases. Oxidative Med. Cell. Longevity, 2019, vol. 2019 (1), p. 9613090.
19. Munteanu C. et al. Redox homeostasis, gut microbiota, and epigenetics in neurodegenerative diseases: a systematic review. Antioxidants, 2024, vol. 13 (9), p. 1062.
20. Varadhan S. et al. Evaluation of oxidative stress parameters and antioxidant status in coronary artery disease patients. Arch. Razi Institute, 2022, vol. 77 (2), p. 853.
21. Godbole C. et al. Association of PON1 gene polymorphisms and enzymatic activity with risk of coronary artery disease. Future Cardiol, 2021, vol. 17 (1), pp. 119–126.
22. Decharatchakul N. et al. Association of combined genetic variations in SOD3, GPX3, PON1, and GSTT1 with hypertension and severity of coronary artery disease. Heart Vessels, 2020, vol. 35, pp. 918–929.
23. Zuin M. et al. Paraoxonase‐1 (PON‐1) arylesterase activity levels in patients with coronary artery disease: a meta‐analysis. Dis. Markers, 2022, vol. 2022 (1), pp. 4264314.
24. Bacchetti T. et al. Dysfunctional high-density lipoprotein: The role of myeloperoxidase and paraoxonase-1. Curr. Med. Chem, 2021, vol. 28 (14), pp. 2842–2850.
25. Nalls M.A. et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: a meta-analysis of genome-wide association studies. The Lancet Neurol, 2019, vol. 18 (12), pp. 1091–1102.
26. Fang S. et al. Parkinson’s disease and ischemic stroke: A bidirectional Mendelian randomization study. Translational Stroke Res, 2022, pp. 1–5.
27. Liu T., Guo D., Wei J. The pathogenesis of Parkinson’s disease and crosstalk with other diseases. Biocell, 2024, vol. 48 (8).
28. Mehra S., Sahay S., Maji S.K. α-Synuclein misfolding and aggregation: Implications in Parkinson’s disease pathogenesis. Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics, 2019, vol. 1867 (10), pp. 890–908.
29. Salis Torres A. et al. Mitochondrial dysfunction as a potential mechanism mediating cardiac comorbidities in Parkinson’s disease. Int. J. Mol. Sci, 2024, vol. 25 (20), p. 10973.
30. Quinn P.M.J. et al. PINK1/PARKIN signalling in neurodegeneration and neuroinflammation. Acta Neuropathol. Commun, 2020, vol. 8 (1), p. 189.
31. Ge P., Dawson V.L., Dawson T.M. PINK1 and Parkin mitochondrial quality control: a source of regional vulnerability in Parkinson’s disease. Mol. Neurodegeneration, 2020, vol. 15 (1), p. 20.
32. Ravenhill S.M., Evans A.H., Crewther S.G. Escalating bi-directional feedback loops between proinflammatory microglia and mitochondria in ageing and post-diagnosis of Parkinson’s disease. Antioxidants, 2023, vol. 12 (5), p. 1117.
33. Repici M., Giorgini F. DJ-1 in Parkinson’s disease: clinical insights and therapeutic perspectives. J. Clin. Med, 2019, vol. 8 (9), p. 1377.
34. Tsoporis J.N. et al. Cytoprotective mechanisms of DJ-1: implications in cardiac pathophysiology. Molecules, 2021, vol. 26 (13), p. 3795.
35. Gallinat A. et al. DJ-1 administration exerts cardioprotection in a mouse model of acute myocardial infarction. Front. Pharmacol, 2022, vol. 13, p. 1002755.
36. Orlov M.A. Gen LRRK2. GENOKARTA Geneticheskaya entsiklopediya [Gene LRRK2. GENOCARD Genetic encyclopedia]. 2022, available at: https://www.genokarta.ru/gene/LRRK2
37. Galper J. et al. Lipid pathway dysfunction is prevalent in patients with Parkinson’s disease. Brain, 2022, vol. 145 (10), pp. 3472–3487.
38. De Gonzalo-Calvo D. et al. Circulating non-coding RNAs in biomarker-guided cardiovascular therapy: a novel tool for personalized medicine? Eur. Heart J, 2019, vol. 40 (20), pp. 1643–1650.
39. Shi G. et al. Systematic genome-wide Mendelian randomization reveals the causal links between miRNAs and Parkinson’s disease. Front. Neurosci, 2024, vol. 18, p. 1385675.
40. Tolosa E. et al. Challenges in the diagnosis of Parkinson’s disease. The Lancet Neurol, 2021, vol. 20 (5), pp. 385–397.
41. Chen Q., Huang X., Li R. lncRNA MALAT1/miR-205-5p axis regulates MPP+-induced cell apoptosis in MN9D cells by directly targeting LRRK2. Am. J. Translational Res, 2018, vol. 10 (2), p. 563.
42. Wang H. et al. MiR-205 regulates LRRK2 expression in dopamine neurons in Parkinson’s disease through methylation modification. Iranian J. Public Health, 2022, vol. 51 (7), p. 1637.
43. Soto M. et al. Differential serum microRNAs in premotor LRRK2 G2019S carriers from Parkinson’s disease. Parkinson’s Dis, 2023, vol. 9 (1), p. 15.
44. Ren F. et al. Emerging role of MiR-192-5p in human diseases. Front. Pharmacol, 2021, vol. 12, p. 614068.
45. Yang X. et al. MicroRNA-216a inhibits neuronal apoptosis in a cellular Parkinson’s disease model by targeting Bax. Metabol. Brain Dis, 2020, vol. 35 (4), pp. 627–635.
46. Liu Y. et al. Atherosclerotic conditions promote the packaging of functional microRNA-92a-3p into endothelial microvesicles. Circul. Res, 2019, vol. 124 (4), pp. 575–587.
47. Hou S. et al. MicroRNA-939 governs vascular integrity and angiogenesis through targeting γ-catenin in endothelial cells. Biochem. Biophys. Res. Commun, 2017, vol. 484 (1), pp. 27–33.
48. Wang M. et al. MiR-206 suppresses the progression of coronary artery disease by modulating vascular endothelial growth factor (VEGF) expression. Med. Sci. Monitor: Int. Med. J. Exp. Clin. Res, 2016, vol. 22, p. 5011.
49. Su Y. et al. MicroRNA-181a-5p and microRNA-181a-3p cooperatively restrict vascular inflammation and atherosclerosis. Cell. Death Dis, 2019, vol. 10 (5), p. 365.
50. Yang S. et al. MicroRNA‐216a induces endothelial senescence and inflammation via Smad3/IκBα pathway. J. Cell. Mol. Med, 2018, vol. 22 (5), pp. 2739–2749.
51. Lian Z. et al. Retracted: The anti‐inflammatory effect of microRNA‐383‐3p interacting with IL1R2 against homocysteine‐induced endothelial injury in rat coronary arteries, 2018.
52. Bai F. et al. Simvastatin induces breast cancer cell death through oxidative stress up-regulating miR-140-5p. Aging (Albany NY), 2019, vol. 11 (10), p. 3198.
53. Vahed S.Z. et al. Expression pattern of miR-21, miR-25 and PTEN in peripheral blood mononuclear cells of patients with significant or insignificant coronary stenosis. Gene, 2019, vol. 698, pp. 170–178.
54. Lai Z., Lin P., Weng X., Su J., Chen Y., He Y. et al. MicroRNA-574-5p promotes vascular smooth muscle cell growth during coronary heart disease progression. Biomed Pharmacotherap, 2018, vol. 97, pp. 162–167 (in Russ.). DOI: 10.1016/j.biopha.2017.10.06
55. Ghafouri-Fard S., Gholipour M., Taheri M. Role of microRNAs in the pathogenesis of coronary artery disease. Front. Cardiovasc. Med, 2021, vol. 8, p. 632392.
56. Feng B., Li H. Genetic polymorphism of matrix metalloproteinase‐9 and susceptibility to myocardial infarction: a meta‐analysis. Dis. Markers, 2022, vol. 2022 (1), p. 5507153.
57. Behl T. et al. Multifaceted role of matrix metalloproteinases in neurodegenerative diseases: Pathophysiological and therapeutic perspectives. Int. J. Mol. Sci, 2021, vol. 22 (3), pp. 1413.
58. Grosu L. et al. Parkinson’s disease and cardiovascular involvement: Edifying insights. Biomed. Reports, 2023, vol. 18 (3), pp. 1–8.
59. Kincl V. et al. Parkinson´ s disease cardiovascular symptoms: A new complex functional and structural insight. Eur. J. Neurol, 2024, vol. 31 (2), p. e16110.
60. Suri J.S. et al. Cardiovascular/stroke risk stratification in Parkinson’s disease patients using atherosclerosis pathway and artificial intelligence paradigm: a systematic review. Metabolites, 2022, vol. 12 (4), p. 312.
61. Vallelonga F. et al. Hypotensive episodes at 24-h ambulatory blood pressure monitoring predict adverse outcomes in Parkinson’s disease. Clin. Autonomic Res, 2024, pp. 1–11.
62. Yang M. et al. Epidemiology and risk factors for orthostatic hypotension and its severity in residents aged > 60 years: a cross‐sectional study. Int. J. Hypertension, 2024, vol. 2024 (1), p. 9945051.
63. Bahls M. et al. Physical activity, sedentary behavior and risk of coronary artery disease, myocardial infarction and ischemic stroke: a two-sample Mendelian randomization study. Clin. Res. Cardiol, 2021, pp. 1–10.
64. Acquah A. et al. Daily steps are a predictor of, but perhaps not a modifiable risk factor for Parkinson’s Disease: findings from the UK Biobank. medRxiv, 2024.
65. Lang C. et al. Complexities and challenges of translating intervention success to real world gait in people with Parkinson’s disease. Front. Neurol, 2024, vol. 15, p. 1455692.
66. Csoti I. et al. Polypharmacy in Parkinson’s disease: risks and benefits with little evidence. J. Neural. Transmission, 2019, vol. 126, pp. 871–878.
67. Bane A. et al. Effects of blood flow restriction resistance training on autonomic and endothelial function in persons with Parkinson’s disease. J. Parkinson’s Dis, 2024, preprint, pp. 1–15.
68. Orayj K. Cardiovascular events associated with antipsychotics in newly diagnosed Parkinson’s disease patients: a propensity score matched cohort study. Int. J. General Med, 2021, pp. 2975–2987.
69. Malekizadeh Y. et al. Whole transcriptome in silico screening implicates cardiovascular and infectious disease in the mechanism of action underlying atypical antipsychotic side effects. Alzheimer’s & Dementia: Transl. Res. Clin. Interv, 2020, vol. 6 (1), p. e12078.
70. Beauchemin M. et al. Exploring mechanisms of increased cardiovascular disease risk with antipsychotic medications: risperidone alters the cardiac proteomic signature in mice. Pharmacol. Res, 2020, vol. 152, p. 104589.
71. May M. et al. The antipsychotic medication, risperidone, causes global immunosuppression in healthy mice. PloS one, 2019, vol. 14 (6), p. e0218937.
72. Minhas D., Nidhaan A., Husni M.E. Recommendations for the use of nonsteroidal anti-inflammatory drugs and cardiovascular disease risk: decades later, any new lessons learned? Rheumatic Dis. Clin, 2023, vol. 49 (1), pp. 179–191.
73. Al‐kuraishy H.M. et al. Pros and cons for statins use and risk of Parkinson’s disease: An updated perspective. Pharmacol. Res. Perspect, 2023, vol. 11 (2), p. e01063.
74. Mady A. et al. Determining the role of statins in Parkinson’s disease risk reduction and disease modification: A comprehensive meta‐analysis of 4 million participants’ data. CNS Neurosci. Ther, 2024, vol. 30 (8), p. e14888.
75. Swallow D.M.A. et al. Statins are underused in recent-onset Parkinson’s disease with increased vascular risk: findings from the UK Tracking Parkinson’s and Oxford Parkinson’s Disease Centre (OPDC) discovery cohorts. J. Neurol. Neurosurg. Psych, 2016, vol. 87 (11), pp. 1183–1190.